Accuray is driven by its desire to help cancer patients live longer, better lives without pain or suffering. “Over the past 20 years, we have brought to the market innovations for better cancer care,” says Dr. Lionel Hadjadjeba, President Worldwide Commercial Operations and Corporate Senior Vice President of Accuray. “Cancer has evolved from a deadly disease into a chronic illness. We will continue to invest in cancer research and the further improvement of our technologies.”
Each cancer patient has an individual clinical picture. That is why individualized, tailor-made treatment options are so important in the treatment of cancer. With its TomoTherapy® and CyberKnife® systems, Accuray offers two highly precise radiotherapy solutions for the full range of indications.
“Our CyberKnife is used to treat tumours anywhere in the body with high doses of radiation, so fewer sessions are needed to destroy the diseased cells,” explains Dr. Hadjadjeba. “CyberKnife delivers radiosurgery, and its its unique robotic architecture allows it to treat tumours that are hard to access surgically or are even inoperable in a pain-free way.”
The TomoTherapy system is based on a built-in CT platform which is specifically designed for integrated 3D image guidance. With the TomoTherapy, tumours in critical locations and of simple or complex shapes can be treated with accurate doses of radiation.
“Thanks to our radiotherapy solutions, surgery becomes no longer necessary,” points out Dr. Hadjadjeba. “Large body parts or even multiple tumours can be treated at the same time. And if the cancer comes back, areas that have been treated with radiotherapy in the past can be re-treated with our systems.”
Accuray was founded in 1990 by John R. Adler, who worked as a neurosurgeon and professor at Stanford University. The company acquired TomoTherapy Inc., which was founded in 1999 and developed the TomoTherapy System.
The two companies joined forces in 2011 to be able to work more profitably. Accuray Incorporated, with headquarters in California, has developed into an international organization with customers all over the world, a workforce of 1,000 people and annual revenue of 398.8 million USD in the fiscal year 2016.
Accuray Europe SAS is the subsidiary led by Dr. Hadjadjeba. “Our market is growing at a rate of 3 to 5% each year and still has a lot of potential,” states Dr. Hadjadjeba. “The demand for our solutions is extremely high, and we have already sold more than 800 devices around the world.”
60% of the cancer patients in developed countries are already benefiting from radiotherapy. However, the need is far from being covered, especially in developing countries. Accuray will continue to collaborate with oncology professionals to find new solutions to increase even more the chance for patients to live a long and healthy life despite their cancer diagnosis.